长链非编码RNA CBR3-AS1在乳腺癌中的表达及其功能

目的：探讨长链非编码RNA CBR3-AS1（CBR3-AS1）在乳腺癌中表达及作用。 方法：用qRT-PCR检测70例乳腺癌组织与癌旁组织，以及不同乳腺癌细胞系（MCF-7、MDA-MB-453、SKBR3）与正常乳腺上皮细胞系（HS578Bst）中CBR3-AS1的表达，分析CBR3-AS1表达与乳腺癌患者临床病理参数及预后的关系。将乳腺癌细胞SKBR3分别转染CBR3-AS1干扰序列（干扰组）、CBR3-AS1过表达序列（过表达组）及阴性对照序列（阴性对照组），用MTT法和流式细胞术分别检测各组细胞转染后增殖活力与凋亡的变化。 结果：CBR3-AS1的相对表达量在乳腺癌组织中明显高于癌旁组织，在不同乳腺癌细胞系中均明显高于正常乳腺上皮细胞（均P<0.01）。乳腺癌组织中CBR3-AS1表达与TNM分期（P=0.003）、淋巴结转移（P=0.047）和远处转移（P=0.024）明显有关。CBR3-AS1高表达患者3年无瘤生存率和总生存率均明显低于CBR3-AS1低表达患者（53.3% vs. 70.7%，P=0.003 2；62.8% vs. 78.4%，P=0.005 7）。与阴性对照组比较，干扰组细胞增殖活力明显降低、凋亡率明显升高，过表达组细胞增殖活力明显升高、凋亡率明显降低（均P<0.01）。 结论：CBR3-AS1在乳腺癌中上调表达，并与不良临床病理特征及预后密切相关，机制可能与其过表达可促进乳腺癌细胞增殖，并抑制凋亡有关。    

Expression of long non-coding RNA CBR3-AS1 in breast cancer and its function

Objective: To investigate the expression of long non-coding RNA CBR3-AS1 (CBR3-AS1) in breast cancer and its function.   Methods: The expressions of CBR3-AS1 in 70 paired specimens of breast cancer tissue and adjacent tissue as well as in different breast cancer cell lines (MCF-7, MDA-MB-453 and SKBR3) and normal mammary epithelial cell line (HS578Bst) were detected by qT-PCR. The relations of CBR3-AS1 expression with the clinicopathologic variables and prognosis of the breast cancer patients were analyzed. The breast cancer SKBR3 cells were transfected with CBR3-AS1 interfering sequences (interference group), CBR3-AS1 mimics (overexpression group) and negative control sequences (negative control group) respectively, and then, the proliferative viability and apoptosis of cells of each group after transfection were determined by MTT assay and flow cytometry, respectively. Results: The relative expression level of CBR3-AS1 was significantly increased in breast cancer tissue or each studied breast cancer cell line compared with tumor adjacent tissue or normal mammary epithelial cell line (all P<0.01). The CBR3-AS1 expression in breast cancer tissue was significantly associated with TNM stage (P=0.003), lymph node metastasis (P=0.047) and distant metastasis (P=0.024). The 3-year disease-free survival and overall survival rates in patients with high CBR3-AS1 expression were significantly lower than those in patients with the low CBR3-AS1 expression (53.3% vs. 70.7%, P=0.003 2; 62.8% vs. 78.4%, P=0.005 7). Compared with negative control group, the proliferative viability was significantly reduced and apoptosis rate was significantly increased in cells of interference group, while the proliferative viability was significantly increased and apoptosis rate was significantly reduced in cells of overexpression group (all P<0.01).  Conclusion: The CBR3-AS1 expression is up-regulated in breast cancer and is closely related to the unfavorable clinicopathologic features and poor prognosis of breast cancer patients. The mechanism may probably be associated with its promoting proliferation and inhibiting apoptosis of breast cancer cells.